RESOLVING THE LEDGER
RESOLVING THE LEDGER
This is not a single article. It's every outletcovering this one event, gathered in one place — read AIPROPX's summary, see where the sources line up, then open any report at its origin.
By AIPROPX Editorial Desk · Published · Updated
Everything reported about this story, gathered from 2 sources. Read the summary below, then tap any source to open that report.
A source close to the matter told Reuters there is "no deal" and there "never was a deal to be done" between the two drugmakers
Summary indexed by AIPROPX from Quartz’s reporting — the full article is one click away. Open at source →
2 outlets are covering this. Resolve the ledger to read what they collectively report — the common thread, in plain terms.
Every report on this story — read the summary of each, then open any at its source. AIPROPX summarizes and links; it never reproduces the original.
A source close to the matter told Reuters there is "no deal" and there "never was a deal to be done" between the two drugmakers
Read this report
Proposed $400bn tie-up with Bristol Myers Squibb would create world’s fourth-largest drugmaker but analysts question rationale More than £17bn was wiped off the value of Britain’s biggest drugmaker, AstraZeneca, on Monday after a report that it was in discussions to take over its US rival Bristol Myers Squibb in a deal that would create a near $400bn (£300bn) pharmaceutical group. AstraZeneca, run by Pascal Soriot, its longtime chief executive, had been worth nearly £196bn before the news broke. BMS, headquartered in Princeton, New Jersey, and known for its cancer treatments, was worth $133...
Read this reportAn original, deterministic readout — composed only from the computed coverage facts on this page. No interpretation, no rating; figures only.
AIPROPX has consolidated 2 reports from 2 outlets into a single canonical entry on “Senior source denied AstraZeneca and Bristol Myers Squibb were ever in merger talks.” The covered outlets are based across 2 regions — Other and UK.
The earliest report in this entry came from The Guardian US (Aug 3, 2026, 16:32 UTC); the most recent came from Quartz (Aug 5, 2026, 13:20 UTC).
Comparing the wording across sources, 2 named entities are referenced by multiple outlets and the phrase recurring most across the coverage is “bristol myers squibb”.
3 statements are carried by only one outlet within this set and are not echoed by the others.
Every figure above is a direct count of real published articles. AIPROPX indexes and compares the original reporting — it never rewrites, rates, or editorializes — and each publisher’s full article is always one click away.
Generated by AIPROPX from the source counts above. AIPROPX indexes and resolves coverage; the original publishers are credited and linked at origin in every report.
Coverage from 2 independent outlets across 2 regions — each view opens on its own page.
AIPROPX — “Senior source denied AstraZeneca and Bristol Myers Squibb were ever in merger talks” · https://www.aipropx.com/story/3a6b5fba9070b09197b845b990bf75e2
Other events being covered across multiple sources right now.
Perez Hilton under involuntary psych hold after apparent self-harm livestream: source
5 outletsRep. Wesley Bell talks to voters after projected primary win
6 outletsLebanon-Israel talks in Rome: Israeli forces maintain position in the south
3 outletsEli Roth Claims He ‘Misspoke’ When He Denied Ice Cream Man Uses GenAI
3 outletsParamount's Warner Bros. merger is heading to an antitrust trial in March 2027
3 outletsEighth time a charm? Cincinnati to again consider parks and rec merger